Sells packaging and delivery systems for injectable drugs to drugmakers. Also designs and assembles custom devices for diagnostic and medical-device companies.
10-K for FY2025, filed Feb 17, 2026
Customers buy proprietary products, with sales counted when products ship or are delivered. Sales of contract-manufactured products, some proprietary products, and development and tooling work are counted as West performs the work.
10-K for FY2025, filed Feb 17, 2026We recognize the majority of our revenue, primarily relating to Proprietary Products product sales, at a point in time, following the…View ↗
We recognize revenue relating to our Contract-Manufactured Products product sales and certain Proprietary Products product sales over time…View ↗
We recognize revenue relating to our development and tooling agreements over time, as our performance creates or enhances an asset that the…View ↗
10-K for FY2025, filed Feb 17, 2026
FY2025 revenue by reportable segment ↗$3.1B
10-K for FY2025, filed Feb 17, 2026
$3.1B ↗| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
Proprietary Products
Sold outright
10-K for FY2025, filed Feb 17, 2026 |
81%
FY2022: 83%
|
Proprietary Products, FY2025
$2.5B Sources
|
Sold outright |
|
Contract-Manufactured Products
Recurring
10-K for FY2025, filed Feb 17, 2026 |
19%
FY2022: 17%
|
Contract-Manufactured Products, FY2025
$582M Sources
|
Recurring |
Drugmakers buy packaging and delivery products; diagnostic and medical-device companies buy custom-made components and devices. West sells mainly through its own sales force and distribution network, with limited use of sales agents and regional distributors.
10-K for FY2025, filed Feb 17, 2026
10-K for FY2025, filed Feb 17, 2026
Yes. It kept 16 cents of every revenue dollar as net income in FY2025 and turned 15 cents into free cash flow.
10-Q for Q3 FY2026, filed Oct 29, 2026
Open tableView ↗
8-K, filed Jul 23, 2026
The Company is increasing its full-year 2026 net sales guidance range to $3.345 billion to $3.380 billion, up from $3.295 billion to $3.350…View ↗
8-K, filed Jul 14, 2026
Each of the Agreements has a 10-year term. Each Agreement may be terminated before its respective term expires under certain circumstances…View ↗
8-K, filed Jun 1, 2026
On June 1, 2026, the Company announced the appointment of Michel Lagarde as President and Chief Executive Officer of the Company, effective…View ↗
8-K, filed May 11, 2026
On May 7, 2026, West Pharmaceutical Services, Inc. (the “Company”) determined that the Company has experienced a material cybersecurity…View ↗
Growing. Revenue grew 9% in 4 years, from $2.8B in FY2021 to $3.1B in FY2025, about 2% a year.
Competes with Datwyler, Aptar, SMC, Phillips Medisize, Sharp, and PCI Pharma Services
10-K for FY2025, filed Feb 17, 2026With our range of proprietary technologies, we compete with several companies, such as Datwyler and Aptar, across our Proprietary Products…View ↗
Loading...